Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Moffitt Cancer Center

Sites in Tampa, FL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 8:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
713
Shown on this page
12
Current sort
Recently updated
Campus scope
Moffitt Cancer Center, Tampa, FL
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Moffitt Cancer Center, Tampa, FL. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 601–612 of 713 matching trials with a site at Moffitt Cancer Center, Tampa, FL.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 2 Interventional

Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)

NCT05396885
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple Myeloma
Interventions
anitocabtagene-autoleucel
Biological
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
18
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 31, 2026, 8:16 PM EDT
Active, not recruiting Phase 3 Interventional

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

NCT05501886
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer
Interventions
Gedatolisib, Palbociclib, Fulvestrant, Alpelisib
Drug
Lead sponsor
Celcuity Inc
Industry
Eligibility
18 Years and older
Enrollment
701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
71
States / cities
Birmingham, Alabama • Goodyear, Arizona • Jonesboro, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 31, 2026, 8:16 PM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

NCT06950034
Status at this site: Recruiting
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Refractory Chronic Myelomonocytic Leukemia, CMML, Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemias, Refractory Acute Myeloid Leukemia (AML), Acute Monocytic Leukemia
Interventions
STX-0712
Biological
Lead sponsor
Solu Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Stanford, California • Tampa, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 31, 2026, 8:16 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer

NCT02152631
Site status not listed — check the official record
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Abemaciclib, Erlotinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
54
States / cities
Fayetteville, Arkansas • Jonesboro, Arkansas • Duarte, California + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 31, 2026, 8:16 PM EDT
Active, not recruiting Early Phase 1 Interventional

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

NCT03543969
Site status not listed — check the official record
View directory record Official record
Conditions
Melanoma (Skin), Skin Cancer, Skin Melanoma, Skin Carcinoma
Interventions
Encorafenib, Binimetinib, Nivolumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 31, 2026, 8:16 PM EDT
Recruiting Phase 1 Interventional

DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer

NCT05504707
Status at this site: Recruiting
View directory record Official record
Conditions
Triple Negative Breast Cancer, HER2-negative Breast Cancer
Interventions
HER2 - primed Dendritic cells, HER3 - primed Dendritic cells
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 31, 2026, 8:16 PM EDT
Active, not recruiting No phase listed Observational

"COACH" Study: Individualized COaching in Young Adult Cancer Survivors to Encourage Healthy Behaviors

NCT05434702
Site status not listed — check the official record
View directory record Official record
Conditions
Health Behavior
Interventions
Digital Diet Diary, NHANES Food Frequency Questionnaire (FFQ), Fitbit data collection, Quality of Life questionnaire, Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire, Godin Exercise Leisure-Time questionnaire, Zoom interviews
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
20 Years to 30 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 31, 2026, 8:16 PM EDT
Recruiting Not applicable Interventional

The MIND-BC Study: MIND Diet for Breast Cancer Cognition

NCT07018986
Status at this site: Recruiting
View directory record Official record
Conditions
Breast Cancer
Interventions
MIND Diet, Usual Diet
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 31, 2026, 8:16 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs

NCT07222995
Status at this site: Recruiting
View directory record Official record
Conditions
Skin Cancer
Interventions
Precision Prevention Booklet, Standard Prevention Booklet
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
2,900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
2
States / cities
Tampa, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 31, 2026, 8:16 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer

NCT06319963
Status at this site: Recruiting
View directory record Official record
Conditions
HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
Two IM injections Lenti-HPV-07, One IM injection Lenti-HPV-07
Drug
Lead sponsor
Theravectys S.A.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Orlando, Florida • Tampa, Florida • Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 31, 2026, 8:16 PM EDT
Active, not recruiting Phase 3 Interventional

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

NCT05502237
Site status not listed — check the official record
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Zimberelimab, Domvanalimab, Pembrolizumab, Carboplatin, Cisplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,021 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
11
States / cities
Whittier, California • Washington D.C., District of Columbia • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 31, 2026, 8:16 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

NCT03974022
Site status not listed — check the official record
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Sunvozertinib
Drug
Lead sponsor
Dizal Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
12
States / cities
La Jolla, California • Orange, California • Whittier, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 31, 2026, 8:16 PM EDT

About this Moffitt Cancer Center institution page

What this page lists
ClinicalTrials.gov records that list Moffitt Cancer Center in Tampa, FL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.